Fever (t>38°C) developed in association with drug usage is rare but sometimes severe side effect (SE). It could manifest as single symptom or as a part of such life-threatening syndromes like malignant hyperthermia (MH), serotonin syndrome (SS), neuroleptic malignant syndrome (NMS). Fever could be caused by different therapeutic groups of drugs but the leading positions are occupied by antibiotics (mainly beta-lactams), substances acting on central nervous system (CNS) and chemotherapeutic agents. Main mechanisms are allergic and receptive. Curative measures include discontinuation of the suspected drug, introduction of agents blocking the action of the trigger factor - dantrolene (МН), bromocriptine (NMS), cyproheptadine (SS). Purpose of this review: to present the global and Russian data concerning fever as a drug-induced side effect. To distinguish the groups of patients and drugs of the highest risk. To evaluate aid measures. Results: fever as monosymptom of drug allergy is a difficult condition to be diagnosed and there are only few things that could help to recognize it such as temporal association with the suspected drug use and manifestation of fever along with the following resolution after suspected drug discontinuation and recurrence fever after suspected drug re-challenge. Among four syndromes described in this review such as serum sickness-like reaction (SSLR), NMS, SS and MH just fever at MH is not only a sign like in case of three others but it is significant and life-threatening manifestation and therefore requires additional curative methods (in addition to pharmacological support with dantrolene) – rapid cooling measures: ice-water nasogastric and rectal lavage, infusion of crystalloid solutions cooled up to 4°C, ice packs placing on main blood vessels and liver area, ventilatory measurements.
Published in | American Journal of Pediatrics (Volume 6, Issue 4) |
DOI | 10.11648/j.ajp.20200604.28 |
Page(s) | 495-503 |
Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
Copyright |
Copyright © The Author(s), 2020. Published by Science Publishing Group |
Children, Drug Fever, Malignant Hyperthermia, Serotonin Syndrome, Neuroleptic Malignant Syndrome
[1] | Wilson S. M., Ross J. A. «Temperature disregulation». Drug-induced diseases. Prevention, detection and management. Chapter 54, p 1185-1232. Betesda, 2018. |
[2] | Romanov B. K., Olefir Yu. V., Alyautdin R. N., Glagolev S. V., Polivanov V. A., Ilienko L. I., Alpatov S. P., Bogush N. V., Buyanova N. M., Ganshina I. V., Dibirova G. O., Dmitrieva N. B., Zhukova I. B., Kalinina E. V., Kirillova A. V., Kiseleva N. M., Kukushkin G. V., Leonteva T. I., Maximov M. L., Markina E. V., Mileshina S. E., Yurov D. E. Drug Safety for Children — International Monitoring Data for 50 Years. Safety and Risk of Pharmacotherapy. 2019; 7 (2): 57-64. (In Russ.) https://doi.org/10.30895/2312-7821-2019-7-2-57-64. |
[3] | Jugtawat S, Daulatabadkar B, Pande S. Drug-induced fever versus infection-induced fever. Indian J Drugs Dermatol 2016; 2: 115-6. |
[4] | Patel, R. A. and Gallagher, J. C. (2010), Drug Fever. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 30: 57-69. doi: 10.1592/phco.30.1.57. |
[5] | Dominique Vodovar, Christine Le Beller, Bruno Mégarbane, Agnès Lillo-Le Louet, Drug fever, Adverse Drug Reaction Bulletin, 10.1097/FAD.0000000000000002, 284, 1, (1-4), (2014). |
[6] | Jake Laun, Katie Laun, Adeel Farooqi, David J Smith, Heparin-Induced Fever: A Case Report and Literature Review, Journal of Burn Care & Research, 10.1093/jbcr/irz064, (2019). |
[7] | Kenichiro Yaita, Yoshiro Sakai, Kenji Masunaga, Hiroshi Watanabe, A Retrospective Analysis of Drug Fever Diagnosed during Infectious Disease Consultation, Internal Medicine, 10.2169/internalmedicine.55.5740, 55, 6, (605-608), (2016). |
[8] | Sharif S, Kong MW, Drakakis J, Cunha BA. Fever of unknown origin (FUO) in a renal transplant recipient due to drug fever from sirolimus. Infection. 2016; 44 (4): 559-561. |
[9] | Martha Belete, Colin Bigham, Beta-lactam-induced pyrexia, Journal of the Intensive Care Society, 10.1177/1751143715594628, 17, 1, (84-84), (2016). |
[10] | Jamshidi N, Dawson A. The hot patient: acute drug-induced hyperthermia [published correction appears in Aust Prescr. 2019 Apr; 42 (2): 79]. Aust Prescr. 2019; 42 (1): 24-28. doi: 10.18773/austprescr.2019.006. |
[11] | Fang Y, Xiao H, Tang S, et al. Clinical features andtreatment of drug fever caused by anti-tuberculosis drugs. Clin Resp J 2016; 10: 449-54. |
[12] | Shao QQ, Qin L, Ruan GR, Chen RX, Luan ZJ, Ma XJ. Tigecycline-induced Drug Fever and Leukemoid Reaction: A Case Report. Medicine (Baltimore). 2015; 94 (45): e1869. doi: 10.1097/MD.0000000000001869. |
[13] | Gu W, Shi D, Mi N, Pang X, Liu W. Physician, Beware! Drug Fever Without Skin Rashes Can Be Caused by Minocycline. J Investig Allergol Clin Immunol. 2017; 27 (4): 268-269. doi: 10.18176/jiaci.0164. |
[14] | Swe T, Ali M, Naing AT. Drug fever induced by piperacillin/tazobactam in an elderly patient with underlying human immunodeficiency virus (HIV) infection. BMJ Case Rep. 2016; 2016: bcr 2016215814. Published 2016 Jul 20. doi: 10.1136/bcr-2016-215814. |
[15] | Portel L, Hilbert G, Gruson D, Favier JC, Gbikpi-Benissan G, Cardinaud JP. Malignant hyperthermia and neuroleptic malignant syndrome in a patient during treatment for acute asthma. Acta Anaesthesiol Scand. 1999; 43 (1): 107-110. doi: 10.1034/j.1399-6576.1999.430123.x. |
[16] | Simon LV, Hashmi MF, Callahan AL. Neuroleptic Malignant Syndrome. In: Stat Pearls. Treasure Island (FL): Stat Pearls Publishing; June 3, 2020. |
[17] | Psareva N. V. "Analysis of the relationship between the efficacy and safety of amitriptyline and pipofezine in patients with depressive disorders with the influence of genetic polymorphism of CYP2D6". Drugs and rational pharmacotherapy. 2014, №2, pp. 26-31. |
[18] | Yıldırım V, Direk MÇ, Güneş S, Okuyaz Ç, Toros F. Neuroleptic Malignant Syndrome Associated with Valproate in an Adolescent. Clin Psychopharmacol Neurosci. 2017; 15 (1): 76-78. doi: 10.9758/cpn.2017.15.1.76. |
[19] | Silva RR, Munoz DM, Alpert M, Perlmutter IR, Diaz J. Neuroleptic malignant syndrome in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1999; 38 (2): 187-194. doi: 10.1097/00004583-199902000-00018. |
[20] | Westfall C, Mullett CJ, Nield LS. Index of suspicion. Case 2: Fever and Irritability in a 15-year-old Boy With Autism. Pediatr Rev. 2015; 36 (7): 313-315. doi: 10.1542/pir.36-7-313. |
[21] | Wigen CL, Goetz MB. Serotonin syndrome and linezolid. Clin Infect Dis. 2002; 34 (12): 1651-1652. doi: 10.1086/340710. |
[22] | Packer S, Berman SA. Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid. Am J Psychiatry. 2007; 164 (2): 346-347. doi: 10.1176/ajp.2007.164.2.346b. |
[23] | Foong AL, Grindrod KA, Patel T, Kellar J. Demystifying serotonin syndrome (or serotonin toxicity). Can Fam Physician. 2018; 64 (10): 720-727. |
[24] | Morris R, Matthes J. Serotonin syndrome in a breast-fed neonate. BMJ Case Rep. 2015; 2015: bcr2015209418. Published 2015 May 6. doi: 10.1136/bcr-2015-209418. |
[25] | Fischer Fumeaux CJ, Morisod Harari M, Weisskopf E, et al. Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence - an update. Expert Opin Drug Saf. 2019; 18 (10): 949-963. doi: 10.1080/14740338.2019.1658740. |
[26] | Phan H, Casavant MJ, Crockett S, Lee A, Hall MW, Nahata MC. Serotonin syndrome following a single 50 mg dose of sertraline in a child. Clin Toxicol (Phila). 2008; 46 (9): 845-849. doi: 10.1080/15563650801938654. |
[27] | Direk MÇ, Yıldırım V, Güneş S, Bozlu G, Okuyaz Ç. Serotonin Syndrome after Clomipramine Overdose in a Child. Clin Psychopharmacol Neurosci. 2016; 14 (4): 388-390. doi: 10.9758/cpn.2016.14.4.388. |
[28] | Werneke U, Jamshidi F, Taylor DM, Ott M. Conundrums in neurology: diagnosing serotonin syndrome - a meta-analysis of cases. BMC Neurol. 2016; 16: 97. Published 2016 Jul 12. doi: 10.1186/s12883-016-0616-1. |
[29] | Laha S, Giri PP, Saha A, Gupta PP, De A. Life-threatening Episodes of Malignant Hyperthermia Following Halothane Anesthesia in Three Children: A Case Series and Review of Literature. Indian J Crit Care Med. 2019; 23 (1): 47-50. doi: 10.5005/jp-journals-10071-23112. |
[30] | Kolesnikova E. Yu., Zhuravleva E. O., Asetskaya I. L., Zatolochina K. E. Identification and assessment of cases of malignant hyperthermia triggering under anaesthetic management: analysis of spontaneous reporting database. Safety and Risk of Pharmacotherapy. 2015; (3): 5-12. (In Russ.) |
[31] | Yang L, Tautz T, Zhang S, Fomina A, Liu H. The current status of malignant hyperthermia. J Biomed Res. 2019; 34 (2): 75-85. doi: 10.7555/JBR.33.20180089. |
[32] | Chan TY, Bulger TF, Stowell KM, et al. Evidence of malignant hyperthermia in patients administered triggering agents before malignant hyperthermia susceptibility identified: missed opportunities prior to diagnosis. Anaesth Intensive Care. 2017; 45 (6): 707-713. doi: 10.1177/0310057X1704500610. |
[33] | Sinha AK, Kumari P, Vaghela MM, Sinha C, Kumar B. Postoperative Malignant Hyperthermia- A Medical Emergency: A Case Report and Review of Literature. J Clin Diagn Res. 2017; 11 (4): PD01-PD02. doi: 10.7860/JCDR/2017/20531.9493. |
[34] | Şahin SH, İnan M, Aksu B, Öner N, Çolak A, Güzel A. Post-Operative Malignant Hyperthermia in a Child after Colon Interposition. Turk J Anaesthesiol Reanim. 2015; 43 (6): 431-433. doi: 10.5152/TJAR.2015.04809. |
[35] | Liu ST, Liu LF, Wang SY. Treatment of Malignant Hyperthermia without Dantrolene in a 14-year-old Boy. Chin Med J (Engl). 2017; 130 (6): 755-756. doi: 10.4103/0366-6999.201616. |
[36] | Mathur PR, Rundla M, Jain N, Mathur V. Malignant hyperthermia in a 6-month-old infant. Saudi J Anaesth. 2016; 10 (3): 353-355. doi: 10.4103/1658-354X.174915. |
[37] | Litman RS, Smith VI, Larach MG, et al. Consensus Statement of the Malignant Hyperthermia Association of the United States on Unresolved Clinical Questions Concerning the Management of Patients With Malignant Hyperthermia. Anesth Analg. 2019; 128 (4): 652-659. doi: 10.1213/ANE.0000000000004039. |
[38] | Turhan KS, Baytaş V, Batislam Y, Ozatamer O. Delayed onset malignant hyperthermia after sevoflurane. Case Rep Anesthesiol. 2013; 2013: 712710. doi: 10.1155/2013/712710. |
[39] | Wackernagel D, Obaya S, Nydert P. Dalteparin-sodium induced drug fever in a neonate. BMJ Case Rep. 2016; 2016: bcr2016217621. Published 2016 Oct 13. doi: 10.1136/bcr-2016-217621. |
[40] | Rosenberg H, Sambuughin N, Riazi S, Dirksen R. Malignant Hyperthermia Susceptibility. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. GeneReviews®. Seattle (WA): University of Washington, Seattle; December 19, 2003. |
APA Style
Sergey Postnikov, Natalia Teplova, Aleksey Ermilin, Marya Kostyleva, Anna Gratzyanskaya, et al. (2020). Fever as an Adverse Drug Reaction of Different Therapeutic Groups. American Journal of Pediatrics, 6(4), 495-503. https://doi.org/10.11648/j.ajp.20200604.28
ACS Style
Sergey Postnikov; Natalia Teplova; Aleksey Ermilin; Marya Kostyleva; Anna Gratzyanskaya, et al. Fever as an Adverse Drug Reaction of Different Therapeutic Groups. Am. J. Pediatr. 2020, 6(4), 495-503. doi: 10.11648/j.ajp.20200604.28
AMA Style
Sergey Postnikov, Natalia Teplova, Aleksey Ermilin, Marya Kostyleva, Anna Gratzyanskaya, et al. Fever as an Adverse Drug Reaction of Different Therapeutic Groups. Am J Pediatr. 2020;6(4):495-503. doi: 10.11648/j.ajp.20200604.28
@article{10.11648/j.ajp.20200604.28, author = {Sergey Postnikov and Natalia Teplova and Aleksey Ermilin and Marya Kostyleva and Anna Gratzyanskaya and Yulia Eremina and Galina Chervyakova}, title = {Fever as an Adverse Drug Reaction of Different Therapeutic Groups}, journal = {American Journal of Pediatrics}, volume = {6}, number = {4}, pages = {495-503}, doi = {10.11648/j.ajp.20200604.28}, url = {https://doi.org/10.11648/j.ajp.20200604.28}, eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajp.20200604.28}, abstract = {Fever (t>38°C) developed in association with drug usage is rare but sometimes severe side effect (SE). It could manifest as single symptom or as a part of such life-threatening syndromes like malignant hyperthermia (MH), serotonin syndrome (SS), neuroleptic malignant syndrome (NMS). Fever could be caused by different therapeutic groups of drugs but the leading positions are occupied by antibiotics (mainly beta-lactams), substances acting on central nervous system (CNS) and chemotherapeutic agents. Main mechanisms are allergic and receptive. Curative measures include discontinuation of the suspected drug, introduction of agents blocking the action of the trigger factor - dantrolene (МН), bromocriptine (NMS), cyproheptadine (SS). Purpose of this review: to present the global and Russian data concerning fever as a drug-induced side effect. To distinguish the groups of patients and drugs of the highest risk. To evaluate aid measures. Results: fever as monosymptom of drug allergy is a difficult condition to be diagnosed and there are only few things that could help to recognize it such as temporal association with the suspected drug use and manifestation of fever along with the following resolution after suspected drug discontinuation and recurrence fever after suspected drug re-challenge. Among four syndromes described in this review such as serum sickness-like reaction (SSLR), NMS, SS and MH just fever at MH is not only a sign like in case of three others but it is significant and life-threatening manifestation and therefore requires additional curative methods (in addition to pharmacological support with dantrolene) – rapid cooling measures: ice-water nasogastric and rectal lavage, infusion of crystalloid solutions cooled up to 4°C, ice packs placing on main blood vessels and liver area, ventilatory measurements.}, year = {2020} }
TY - JOUR T1 - Fever as an Adverse Drug Reaction of Different Therapeutic Groups AU - Sergey Postnikov AU - Natalia Teplova AU - Aleksey Ermilin AU - Marya Kostyleva AU - Anna Gratzyanskaya AU - Yulia Eremina AU - Galina Chervyakova Y1 - 2020/12/16 PY - 2020 N1 - https://doi.org/10.11648/j.ajp.20200604.28 DO - 10.11648/j.ajp.20200604.28 T2 - American Journal of Pediatrics JF - American Journal of Pediatrics JO - American Journal of Pediatrics SP - 495 EP - 503 PB - Science Publishing Group SN - 2472-0909 UR - https://doi.org/10.11648/j.ajp.20200604.28 AB - Fever (t>38°C) developed in association with drug usage is rare but sometimes severe side effect (SE). It could manifest as single symptom or as a part of such life-threatening syndromes like malignant hyperthermia (MH), serotonin syndrome (SS), neuroleptic malignant syndrome (NMS). Fever could be caused by different therapeutic groups of drugs but the leading positions are occupied by antibiotics (mainly beta-lactams), substances acting on central nervous system (CNS) and chemotherapeutic agents. Main mechanisms are allergic and receptive. Curative measures include discontinuation of the suspected drug, introduction of agents blocking the action of the trigger factor - dantrolene (МН), bromocriptine (NMS), cyproheptadine (SS). Purpose of this review: to present the global and Russian data concerning fever as a drug-induced side effect. To distinguish the groups of patients and drugs of the highest risk. To evaluate aid measures. Results: fever as monosymptom of drug allergy is a difficult condition to be diagnosed and there are only few things that could help to recognize it such as temporal association with the suspected drug use and manifestation of fever along with the following resolution after suspected drug discontinuation and recurrence fever after suspected drug re-challenge. Among four syndromes described in this review such as serum sickness-like reaction (SSLR), NMS, SS and MH just fever at MH is not only a sign like in case of three others but it is significant and life-threatening manifestation and therefore requires additional curative methods (in addition to pharmacological support with dantrolene) – rapid cooling measures: ice-water nasogastric and rectal lavage, infusion of crystalloid solutions cooled up to 4°C, ice packs placing on main blood vessels and liver area, ventilatory measurements. VL - 6 IS - 4 ER -